These results and the restricted expression of RHAMM in normal tissues, which contrasts with constitutive and widespread CD44 expression, predict that RHAMM is an attractive potential cancer therapy target for the breast cancer subtypes that use this HA receptor to promote invasion and metastasis. The gene discussed is CD44; the disease is breast cancer.